ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301
19 août 2024 08h00 HE
|
ImmuneSensor Therapeutics
Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
08 août 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates
Alumis Initiates ONWARD Phase 3 Clinical Program Evaluating ESK-001, an Oral TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis
29 juil. 2024 08h00 HE
|
Alumis Inc.
Alumis announced that patient dosing has commenced in the ONWARD Phase 3 clinical program for ESK-001 for the treatment of psoriasis.
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
26 juil. 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
18 juil. 2024 19h08 HE
|
Artiva Biotherapeutics Inc.
Artiva Biotherapeutics Announces Pricing of Upsized $167.0 Million Initial Public Offering
Synthetic Immunology Market Report 2024 with Profiles of ADC Therapeutics, BioNTech, Camena Bioscience, CRISPR Therapeutics, Editas Medicine, Sherlock Biosciences, Synlogic Therapeutics & Synthego
04 juil. 2024 07h28 HE
|
Research and Markets
Dublin, July 04, 2024 (GLOBE NEWSWIRE) -- The "Synthetic Immunology Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Synthetic Immunology Market is...
Alumis Announces Pricing of Initial Public Offering
27 juin 2024 23h57 HE
|
Alumis Inc.
Alumis, a clinical-stage biopharmaceutical company developing oral therapies for immune mediated diseases, announces pricing of initial public offering
Antion Biosciences announces development of safety-enhanced and off-the-shelf CAR T-cells for autoimmune disease
22 mai 2024 06h55 HE
|
ANTION BIOSCIENCES SA
Aiming for a best-in-class solution to treat and cure B-cell driven autoimmune diseases
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
17 mai 2024 07h00 HE
|
Autolus Therapeutics plc
Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
13 mai 2024 08h00 HE
|
Exagen Inc.
CARLSBAD, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31,...